Posts

NutraLife Bioscience, Inc. Receives License to Grow and Process Industrial Hemp

Summary: NutraLife Biosciences, Inc. Receives License to Grow and Process Industrial Hemp in  the state of Wisconsin.

NutraLife Biosciences, Inc. (“the Company” or “NutraLife”) (OTCQB: NLBS) has received two licenses from the Wisconsin Department of Agriculture to grow and process industrial hemp within the state. The Company plans to develop  efficient, cost reducing growing systems and processing technologies for industrial hemp.

Edgar Ward, Founder and CEO of NutraLife commented: “As a company entering the bio life sciences space it is our goal to become vertically integrated as a trusted supplier of raw bulk materials and insure the efficacy and quality of the products produced.”

According to a recent Hemp Industry Daily report, Wisconsin was deemed a ‘new and emerging market’ for hemp and hemp production. The report also names Wisconsin the ‘fastest-moving state yet to allow hemp industry to take root.’ Other up and coming states include California and Virginia, to name a few.

The Company’s in-house products include the NutraHempCBD and NutraSpray brands. The Company manufactures 100% of its in-house products at its FDA approved facility in accordance with GMP.  The Company developed its first branded products in 2013. The Company’s product development, testing and research is conducted by four chemists under the supervision of Mr. Ward.

NutraLife Biosciences, Inc., formerly known as NutraFuels, Inc., (“NutraLife” or the “Company”) also recently announced a name change to NutraLife BioSciences, Inc. and new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

 

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

 

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraLife BioSciences, Inc., (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc., to Change its Name to NutraLife BioSciences, Inc. and Proposed Symbol to NLBS

Coconut Creek, FL, March 05, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (the “Company”) is pleased to announce a name change to NutraLife  BioSciences, Inc. and a new stock trading symbol, NLBS.  The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations. Commencing March 6, 2019, the Company’s common shares will trade with the stock ticker symbol “NLBS”.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. fka NutraLife Biosciences, Inc. Explores New Delivery Systems with Pharmaceutical GMP Manufacturer

Coconut Creek, FL, Feb. 28, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc., fka NutraLife Biosciences, Inc. (“the Company” or “NutraFuels”) (OTCQB: NTFU) plans to explore additional options for delivery systems for its nutraceutical and wellness products and pharmaceutical delivery systems.

“We are excited to be exploring our capabilities in the life sciences space by engaging in the research and development of more formulations and enhanced delivery systems with an experienced cGMP pharmaceutical manufacturer,” said Edgar Ward, CEO and Founder of NutraFuels.

The Company plans to explore these various pharmaceutical formulations and delivery systems while utilizing the valuable experience of a cGMP pharmaceutical manufacturer.

The Company manufactures and distributes private label and its own branded products under its NutraHempCBD and NutraSpray brands. The Company’s product development, testing and research are conducted by four chemists under the supervision of Mr. Ward. The Company manufactures 100% of its products at its FDA registered facility in accordance with GMP standards.

The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, the Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. The Company’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

* This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements

This communication contains statements of a forward-looking nature about NutraFuels, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. Tests Confirm High Quality Proprietary Ultra Shear Technology Platform

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. Tests Confirm High Quality Proprietary Ultra Shear Technology Platform

Coconut Creek FL, Feb. 22, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. fka NutraLife BioSciences, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”), in a joint venture, today announce that analytical tests on Hemp-derived CBD oil processed by PBI’s Ultra Shear Technology™ (UST) platform confirm that: (i) UST processing results in the development of a true CBD oil nanoemulsion, and (ii) CBD is neither lost nor modified during the UST process (> 99% recovery).

The proprietary UST platform combines ultra-high pressure with extreme shearing forces to create very small, nano-scale mixtures of fluids that otherwise do not mix, resulting in a highly stable homogenized solution called nanoemulsions.

Dr. Vera Gross, Senior Scientist R&D at PBI, commented: “To determine if the UST process resulted in a loss or modification of CBD during processing, we enlisted the help of our collaborator NutraFuels, Inc. NTFU has an FDA-inspected, highly-qualified analytical laboratory with state-of-the-art equipment and well-trained chemists with years of experience in laboratory testing.”

For many oil-based nutritional and therapeutic products, such as CBD-infused nutraceuticals, nanoemulsions offer superior water solubility and increased bioavailability for improved absorption. Consequently, there is a significant need to develop reliable, scalable methods to process CBD oil into high-quality nanoemulsions, with minimal loss of CBD during the process.

Mr. Cooper Dodd, an R&D Scientist at NTFU, said: “Using a powerful laboratory method called HPLC to measure the concentrations of CBD and potential impurities, we determined that no appreciable amount of CBD was lost during the UST process. These results compare well to our standard processing method of ultrasonication, which can carry a risk of measurable loss of CBD, and sometimes create the appearance of impurities if not performed properly. While there is more work to be done, as a nutraceutical manufacturer with products already on the market, we see these results as a robust leap towards better optimization of our CBD-enhanced products.”

Dr. Gross, Director of Applications Development from PBI, added: “To determine if UST processing of CBD oil generates true nanoemulsions, we asked an independent, university-affiliated laboratory to determine the size of oil droplets in post-UST processed material using a universally-accepted sizing method called DLS. Their results showed that post-UST processed oil droplets were approximately 65 nm in size, well within the range of 20-200 nm generally accepted as defining a true nanoemulsion (Nano- and Microscale Drug Delivery Systems, 2017).”

Professor Keith Warriner, Professor of Food Science at the University of Guelph, and a recognized expert in the cannabis industry, commented: “The data disclosed today on UST-generated nanoemulsions of CBD oil are very impressive. Creating nanoemulsions of CBD oil with full preservation of CBD throughout the process, while not generating impurities, remains a significant challenge in the industry. These data offer great promise to the future.”

Professor Warriner continued: “Although there is great excitement over CBD-infused edibles and beverages, and rightfully so, I believe that CBD-infused topicals may be an even greater market for CBD products in the near future. However, to be successful, it is imperative that topicals be highly stable, bioavailable and readily absorbent nanoemulsions. After a review of the data released today, the UST process appears to be a leading candidate to fill that need.”

Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We were very excited to share the news just last week of PBI’s visually obvious successful production of water-soluble CBD Oil. However, the addition of these scientific validations of our successful achievement of creating nanoemulsions by the UST platform, and our preservation of CBD levels all the way through to the finished product are frankly the crowning touch to the news of these accomplishments.  We believe our proprietary Ultra Shear Technology will be a pivotal change agent strongly affecting the future of many major existing product areas, spanning foods, nutraceuticals, therapeutics, cosmetics, lubricants, paints, and other industries.”

About NutraFuels, Inc.

NutraFuels, Inc. fka NutraLife BioSciences, Inc. was founded in 2010 and has evolved into a branded and private label developer, distributor and Food and Drug Administration registered (FDA) manufacturer. NTFU’s products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraFuels’ manufacturing process received the Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NTFU’s product testing and research and development are conducted by four chemists under the direction of NTFU’s founder and Chief Executive Officer, Edgar Ward.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO ’s primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward-Looking Statements

This press release contains forward-looking statements about NutraFuels, Inc. and Pressure BioSciences, Inc. (collectively the “Companies”). These statements relate to future events or the Companies’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause each of the Companies industry results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Companies have based these forward-looking statements largely on their current expectations and projections about future events and financial trends that the Company believes may affect their respective financial condition, results of operations, business strategy, and financial needs. These statements are only predictions based on each of the Companies current expectations and projections about future events. Investors should not place undue reliance on these statements. In evaluating these statements, Investors should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause the Companies’ actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in each of the Companies’ Annual Reports and other reports filed from time to time with the Securities & Exchange Commission (SEC). More detailed information about these risk factors are set forth in the Companies’ filings with the SEC. The Companies encourage Investors to review these risk factors. The Companies undertake no obligation to update any of the information included in this release, except as otherwise required by law.

NutraFuels, Inc. Founds NutraDerma Technologies and Acquires Patented All-Natural Skin Patch For Deet-Free Mosquito Deterrent and Creates New Subsidiary, NutraDerma Technologies, Inc.

To read this press release on OTCMarkets.com visit:

NutraFuels, Inc. Founds NutraDerma Technologies and Acquires Patented All-Natural Skin Patch For Deet-Free Mosquito Deterrent and Creates New Subsidiary, NutraDerma Technologies, Inc.

Coconut Creek, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) — –via NEWMEDIAWIRE — NutraFuels, Inc. (NTFU), soon to be NutraLife BioScience, Inc.  (“NutraFuels” or the “Company”) has acquired a patent for a unique and natural formulation that deters insects including mosquitoes through a dermal delivery system patch. On January 28, 2019, NutraFuels founded a new wholly owned subsidiary, NutraDerma Technologies, Inc. (“NutraDerma”) to commercialize the patented dermal patch.

* This product is not intended to diagnose, treat, cure or prevent any disease.The all-natural insect deterrent dermal patch is the first planned product for NutraDerma. The patented patch uses natural ingredients such as Vitamin B1 to ward off insects. NutraFuels founded NutraDerma to commercialize the all-natural dermal mosquito patch upon compliance with applicable regulatory requirements.

NutraDerma plans to develop other nutraceutical, skin care, cosmetic and wellness dermal skin patches including vitamin supplement patches and various formulations designed to harness the benefits of combining key ingredients and technologies to support health and wellness. With the acquisition of its new patent, NutraDerma has taken its first step towards entering the bio life sciences market.

According to the American Mosquito Control Association (“AMCA”), there are more than one million Malaria-related deaths and 300 – 500 million cases are reported annually throughout the world. As the Center for Disease Control (“CDC”) reports, Zika is still a threat internationally as well.

NutraFuels, Inc is a fully reporting company with a class of securities registered with the U.S. Securities & Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

* These statements have not been evaluated by the Food and Drug Administration.

Forward Looking Statements
This communication contains statements of a forward-looking nature about NutraFuels, Inc. fka NutraLife BioSciences, Inc., and its wholly owned subsidiary, NutraDerma Technologies, Inc. (the “Company”). These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that Company’s current expectations and projections concerning its ability to commercialize the patented insect dermal patch are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

NutraFuels, Inc. and Pressure BioSciences, Inc. to Collaborate on the Development of Water-Soluble Nanoemulsion-based NutraceuticalsView Press Release on OTCMarkets.com

Coconut Creek, FL, Jan. 30, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (OTCQB: NTFU) (NTFU) and Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) (together, the “Companies”) today announced a collaboration to advance the development of a new generation of health and wellness nutraceutical products based on processing by PBI’s proprietary Ultra Shear Technology (UST™) platform. The Companies believe that nanoemulsions prepared by the UST Platform will have improved quality and effectiveness compared to current emulsions, which will help to facilitate the development of a new generation of improved nutraceutical and other emulsion-based products, such as cosmetics.

PBI is a leader in the development and sale of enabling high pressure-based instruments, consumables, and related services for the life sciences industry.  PBI has more than 300 high-pressure instruments installed in over 200 life sciences laboratories worldwide, including in some of the world’s leading academic, government, and biopharmaceutical laboratories.

 NTFU manufactures and distributes nutritional and dietary supplements focusing on in-house product development and the highest manufacturing standards. All quality control testing and manufacturing processes are in compliance with FDA and cGMP standards. NTFU has developed multiple products for the wellness and nutraceutical markets, including formulas to support energy and focus, sleep, stress, joints, and weight loss.

 Edgar J. Ward, President and CEO of NTFU, said: “We pride ourselves in ensuring that we incorporate the highest level of quality possible in our manufactured products. When we heard that PBI was developing their new, proprietary UST processing platform, and learned of its potential to significantly increase the quality and effectiveness of nutraceutical products, we spoke with PBI and offered to help accelerate its commercial introduction. We are thrilled to be working with such experienced scientific leaders and innovators, in a program that we believe can change lives worldwide for the better.”

 Mr. Ward continued: “We believe PBI’s UST platform has the potential to create long-term room temperature stable, water-soluble nanoemulsions of oil-based solutions. Nanoemulsions are known to offer greater stability and bioavailability than the standard macroemulsions used today in nutraceuticals, cosmetics, and other industries.  We are excited to have the opportunity to work with a life science industry leader in the optimization of a process that has the potential to bring higher quality not just to our products, but to nutraceutical products worldwide.”

 Dr. Bradford A. Young, Chief Commercial Officer of PBI, commented: “We are pleased to have the opportunity to work with NTFU’s scientists and manufacturing personnel in the development of new and improved nutraceutical products utilizing our UST platform. This proprietary technology employs ultra-high pressure and extreme shearing forces to create nano-scale emulsions of oil and water with long-term stability. For many oil-based products, the ability to create very small, nanometer-sized oil droplets that can effectively dissolve in water (nanoemulsions) can improve a product’s appearance, sensory and medicinal benefits. There is a large and growing market opportunity for nutraceutical products with proven health and wellness benefits. We believe PBI’s UST platform can help manufacturers accelerate growth and success in this market with higher quality, water-soluble, oil-based products with superior dietary absorption and shelf-life.”

 Mr. Richard T. Schumacher, President and CEO of PBI, added: “We are excited to work with Edgar and his NTFU team in the optimization of our UST platform, which we believe will result in the development of new and beneficial health and wellness products.  The staff at NTFU has years of experience in manufacturing nutraceutical products in a quality environment. They also have access to both raw materials and finished goods, both of which are needed for optimization.  Finally, they have an existing analytical laboratory with state-of-the-art equipment and well-trained chemists who can perform testing on both pre and post-processed materials, which will be invaluable to the optimization process. This collaboration clearly supports both company’s strategic objectives: we look forward to an exciting and mutually beneficial relationship with our colleagues at NutraFuels.”

About Pressure BioSciences, Inc. 

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of high pressure-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bioterror applications. Additionally, we are actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired protein disaggregation and refolding technology from BaroFold, Inc. to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (UST) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

 About NutraFuels, Inc.

 NutraFuels, Inc was founded in 2010 and has evolved into a branded and private label developer, distributor and Food and Drug Administration registered (FDA) manufacturer. NTFU’s products include a range of nutraceutical, wellness, and CBD products as well as a cosmetics line. NutraFuels’ manufacturing process received the Good Manufacturing Processes Standard (GMP) certification. Its products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. NTFU’s product testing and research and development is conducted by four chemists under the direction of NTFU’s founder and Chief Executive Officer, Edgar Ward.

Forward-Looking Statements

This press release contains forward-looking statements. These statements relate to future events or the Companies’ future financial performance and involve known and unknown risks, uncertainties and other factors that may cause each of the Company’s industry results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. These forward-looking statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Companies have based these forward-looking statements largely on  their current expectations and projections about future events and financial trends that they believe may affect their respective financial condition, results of operations, business strategy, and financial needs. These statements are only predictions based on each of the Companies current expectations and projections about future events. Investors should not place undue reliance on these statements. In evaluating these statements, Investors should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause each of the Company’s actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading “Risk Factors” in each of the Company’s Annual Reports and other reports filed from time to time with the Securities & Exchange Commission (SEC). More detailed information about these risk factors are set forth in the Company’s filings with the SEC. The Companies encourage Investors to review these risk factors. The Companies undertake no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about the Companies and this press release, please click on the following website link: 

www.nutrafuels.com        

Telephone 888-509-8901

http://www.pressurebiosciences.com  

NutraFuels, Inc. and Pressure BioSciences, Inc. to Collaborate on the Development of Water-Soluble Nanoemulsion-based NutraceuticalsView Press Release on OTCMarkets.com

Selling cannabis or hemp on Times Square? Florida company makes marketing history

Check out our news article on FloridaPolitics.com

While CBS still won’t run medical marijuana advertisements during the Super Bowl, a Florida company just ran the first-ever ads for cannabis-based products in Times Square.

NutraFuels, a nutraceutical manufacturing company with a line of hemp-derived CBD products under the brand NutraHempCBD (www.nutrahempcbd.com) was in the first digital billboard cannabis campaign in the famed intersection.

“This ad campaign was our way to celebrate the deregulation of hemp and create awareness of its health and wellness benefits,” said Edgar Ward, president and CEO of NutraFuels.

While companies with hemp and cannabis products in the past have tried to buy ad space in Times Square before, the marketing debuted concurrently with a change in the law.

Until this year, federal law technically classified all parts of the cannabis plant as marijuana, a scheduled narcotic. But the 2018 Farm Bill, as explained by the Billings Institute, differentiated hemp, a part of the plant containing less than 0.3 percent tetrahydrocannabinol. Better known as THC, that’s the stuff that gets people high.

“This campaign was our way of celebrating the Farm Bill and the deregulation of hemp,” said NutraFuels spokeswoman Chloe Sommers.

While the federal government long turned a blind eye to the sale of hemp and CBD oil, which can be sold in all 50 states, major media companies would not accept an advertisement for a product still technically prohibited by law.

It’s much the same reasoning that led CBS to reject an advertisement for Acreage Holdings, which sells medical marijuana, on the grounds the government still considers the sale of the product a crime.

But after the deregulation of hemp and CBD, Honeysuckle Magazine, a lifestyle magazine that regularly writes about the organic products, got approval to run a Times Square billboard campaign.

“It sounded interesting to me, so I jumped on the chance,” said Ronit Pinto, Honeysuckle owner. She offered space to many of advertisers working with her company, and many cannabis-related brands took part, including NutraFuels.

It turns out, the campaign marked the first time anyone sold cannabis-based products like hemp and CBD on a Times Square billboard.

“We started realizing what a great opportunity this involved for a lot of our brand partners, and just kept buying more time,” she said. “It became a huge thing.”

NutraFuels advertised its in-house CBD product NutraHempCBD. The ads provided tremendous exposure for the Coconut Beach-beached company, which employs about 12 people.

The Florida business remains one of the companies that’s continued to participate in the campaign as ad buys stretched into February.

The campaign still faces certain restrictions, Pinto said. There can’t be any pictures of the actual cannabis plant.

Advertisements also can’t show drug paraphernalia as the content must focus on those cannabis products legal under the new farm bill.

But the high-profile advertising could mark the first entry into mainstream marketing for a growing cannabis industry. Maybe the Super Bowl in 2020 will see such products promoted in commercial breaks.

“It’s the right thing to do,” Sommers said. “If you are doing the right thing and doing it by the rules, you should be able to market your product and be seen. CBS is buying into a stigma that’s actually flawed.”

“When it comes to cannabis, until the federal cannabis laws change like the hemp laws were, national media companies will be unlikely to accept their advertising,”  said NutraFuels spokesperson Chloe Sommers. “This positions CBD products well and it looks like it will only get better with time.

“When it comes to cannabis, until the federal cannabis laws change like the hemp laws were, national media companies will be unlikely to accept their advertising. This positions CBD products well and it looks like it will only get better with time.”

Legalization of Industrial Hemp Positions NutraFuels for Market Expansion

NutraFuels, Inc. (“NTFU” or the “Company”), a nutraceutical company with its own line of CBD products under the name NutraHempCBD, applauds the passage of the 2018 Farm Bill allowing federally insured banks to legally work with merchants for product processing as well as the removal of barriers for research and industrial hemp production.

NTFU applauds the passage of the 2018 Farm Bill allowing federally insured banks to legally work with merchants for product processing as well as the removal of barriers for research and industrial hemp production.

The hemp industry has been challenged over the years because of banking restrictions. It has caused challenges from the standpoint of merchant product processing for hemp-derived CBD products. It also caused headwinds with respect to many aspects of the companies operating in the hemp public markets, said Edgar Ward, CEO and Founder of NutraFuels.

Brightfield Group estimates the worth of the hemp CBD market to be $22 Billion by 2022, outpacing the rest of the cannabis market combined. Weve been planning and preparing for an increase in CBD product demand in anticipation of the passage of the 2018 Farm Bill, added Ward.

The updated language from the Farm Bill defines hemp in a way that removes it from the Controlled Substances Act. Going forward, hemp will be classified as an agricultural commodity under federal law. Farmers will now benefit from the removal of barriers to obtaining crop insurance. Shareholders and manufacturers will see the removal of restrictions on importing and exporting hemp which contributes to the projected boost of growth for the hemp industry.

The lack of legal clarification and the longtime stigma around hemp has dampened the business opportunity and created concern for the investment community, said Ward. The new law provides clarity and the legal parameters to enable companies like NutraFuels to capitalize on a more efficient operating environment and market expansion.

NutraFuels is a fully reporting company with a class of securities registered with the SEC. The Companys filings can be viewed at www.sec.gov. NTFUs CBD products and information about the companys direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

Forward Looking Statements
This communication contains statements of a forward-looking nature. These statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as may, will, except, anticipate, aim, estimate, intend, plan, believe, is/are likely to, future or other similar expressions. The Company has based these forward-looking statements largely on the Companys current expectations and projections about future events and financial trends that the Company believes may affect Companys financial condition, results of operations, business strategy, and financial needs. There is no assurance that Companys current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Companys filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled Risk Factors, in the Companys Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Companys management to predict all risk factors, nor can the Company assess the impact of all factors on Companys business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Legalization of Industrial Hemp Positions NutraFuels for Market Expansion

NutraFuels Inc. (OTCQB:NTFU) Prepares For Expansion Into Life Science Field

Coconut Creek, Florida, Dec. 11, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels Inc., publicly traded under the name NTFU (OTCQB: NTFU), manufactures and distributes products adhering to the supplement industry’s highest manufacturing standards. In 2019, it will continue to explore relationships to expand into biotechnology, agriculture, and food processing.

“Diversifying our capabilities strengthens our offerings to our customers, and diversifies our revenues driving shareholder value,” said Edgar Ward, CEO, and Founder of NutraFuels Inc. “We will continue to hold ourselves to the highest standards as we expand into multiple fields of biological life sciences.”

NutraFuels is known for its industry-leading quality standards and cutting-edge manufacturing process. All quality control testing and manufacturing processes are in compliance with FDA and cGMP standards.

NutraFuels is a fully reporting company with a class of securities registered with the SEC. The Company’s filings can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

Forward-Looking Statement

This communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on  April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.

Contact:

NutraFuels, Inc.

6601 Lyons Road, Suite L-6

Coconut Creek, FL  33073

Telephone 888-509-8901

www.NutraFuels.com

www.NutraHempCBD.com

NutraFuels Inc. (OTCQB:NTFU) Prepares For Expansion Into Life Science Field

NutraFuels Inc. (OTCQB:NTFU) Utilizes Nanotechnology for Its CBD-infused Products

To read this press release on OTCMarkets.com visit:

NutraFuels Inc. (OTCQB:NTFU) Utilizes Nanotechnology for Its CBD-infused Products

Coconut Creek, FL, Dec. 10, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NutraFuels, Inc. (“NTFU” or the “Company”), Nutraceutical & CBD Manufacturer & Distributor, announces its use of Nanotechnology in its CBD-infused line of products distributed under its NutraHempCBD brand.

NTFU’s nanotechnology is designed to provide optimal absorption into the body of NTFU’s CBD-infused formulations. Nanotechnology refers to dealing with matter on a very small scale. Nanotechnology allows the smaller cannabinoid particles to be in their most bio-active form for fast absorption and high potency.

“We believe that our proprietary processing utilizing nanotechnology allows for us to create superior products with enhanced bioavailability,” said Edgar Ward, CEO, and Founder of NutraFuels Inc., “We believe that nanotechnology and our enhanced delivery system allows us to give our customers the most effective and efficient delivery system.”

According to Andrij Holian of the Center for Environmental Health Sciences Biomedical and Pharmaceutical Sciences, “Nanoparticles have become a significant interest as a drug delivery system due to their small size and large surface area.”

NutraFuels Inc., a publicly held company traded on the OTCQB under the ticker symbol NTFU, is a nutraceutical company with a line of CBD-infused products known by its in-house brand, NutraHempCBD. Using premium CBD hemp oil, its formulations are designed to promote overall health and wellness. NutraHempCBD products are intended for daily use with observed health benefits including anti-stress, anti-inflammation, calmness to sleep and stay asleep.

NutraHempCBD uses its specialty process to decrease the particle size and uses nano nanoemulsion in its products. For example, its Joint and Pain Balm aids in the alleviation pain with a silky and soothing formulation. Studies suggest that the key ingredient, CBD, may reduce inflammation while interacting with neurotransmitters. The CBD-infused Face Cream is made with Shea Butter and works to maintain elasticity of the delicate facial tissue. CBD studies have shown anti-inflammatory properties as well as a reduction in acne. For a full list of products including Nutrahemp CBD oral sprays, the day and nighttime formulas, and NutraPet oil visit its website.

NutraFuels, Inc is a fully reporting company with a class of securities registered with the U.S. Securities & Exchange Commission (“SEC”). As reported in its Form 8-K filed with the SEC on November 13, 2018, NTFU recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online at www.nutrahempcbd.com and by following the company on Instagram.

Forward-Looking Statements
This communications contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,”, “intends”, “anticipate,” “aim,” “estimate,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. NutraFuels, Inc. (“NTFU” or the “Company”) has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy and financial needs. There is no assurance that Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the Section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission on April 17, 2018. The Company operates in a rapidly evolving environment. New risk factors emerge from time to time, and it is impossible for the Company’s management to predict all risk factors, nor can the Company assess the impact of all factors on Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ from those contained in any forward-looking statement. The Company does not undertake any obligation to update or revise the forward-looking statements except as required under applicable law.